|
| |
 |
| |
Equivalent
Brand Search for USA/Canada Consumers
Generic Search
for USA/Canada Consumers
Product or Generic Search
for USA/Canada Consumers
|
| |
 |
If you are unable to find your required medicine under
'Medicines Search,' Click
here. |
|
|
|
| |
 |
|
| |
|
| |
|
| |
 |
| |
|
| |
|
|
| |
|
|
|
| |
|
| 1 2 3 4 5 6 |
FOR HEALTHCARE PROFESSIONALS
WHAT IS SLIMONA? |
| |
|
SlimonaTM (rimonabant) is a selective CB1 endocannabinoid receptor antagonist
indicated for the treatment of obesity.
SlimonaTM acts by selectively blocking CB1 receptors found in the brain and
peripheral organs involved in glucose and lipid metabolism including adipose
tissue, the liver, gastrointestinal tract and muscle. SlimonaTM by blocking CB1 receptor
decreases the over activity of the endocannabinoid system ( EC System). The
EC system is a recently characterized physiological system that includes
receptor such as the CB1 receptor and is believed to play an important role
in regulating body weight and in controlling energy balance as well as
glucose and lipid metabolism.
SlimonaTM reduces the over activity of endocannabinoid system, improving
lipid and glucose metabolism and regulating food intake and energy balance.
Slimona thus offers a novel therapeutic approach to appetite control, weight
reduction and cardiovascular risk factor management.
|
| |
| INDICATION AND DOSAGE |
Indication: SlimonaTM (rimonabant) is used as an
adjunct therapy to diet and exercise for the treatment of obese patients (BMI
>= 30 kg/m2) or overweight patients (BMI >= 27 kg/m2) with associated
risk factor(s), such as type 2 diabetes or dyslipidemia
Dosage: In adults, the recommended dosage of SlimonaTM is one, 20 mg tablet daily to
be taken in the morning before breakfast. The treatment should be introduced
with a mildly reduced calorie diet.
|
| |
| CLINICAL TRIALS
|
Various
clinical trials have proven the efficacy and safety of rimonabant.
RIMONABANT
CLINICAL TRIALS
|
- Rimonabant In Obesity
(RIO) trials
- RIO-Europe study
- RIO-Lipids study
- RIO-North America (NA)
study
- RIO-Diabetes study
|
- Studies with Rimonabant
and Tobacco Use (STRATUS)
- STRATUS-United States
study
- STRATUS-Europe study
- STRATUS-Worldwide study
|
PHASE
IIIB CLINICAL TRIALS TO ASSESS THE POTENTIAL ROLE OF THE RIMONABANT IN RISK
REDUCTION
|
Eight Studies to assess the potential role of the rimonabant in reducing
the risk of heart attacks or strokes in patients with an abdominal obesity
and other risk factors, and to explore use of rimonabant in preventing and
treating Type 2 diabetes |
Phase IIIb Trials
involving Cardiovascular Disease:
- CRESCENDO : Comprehensive Rimonabant
Evaluation Study of Cardiovascular END points and Outcomes trial
- AUDITOR : Atherosclerosis
Underlying Development Assessed By Intima-Media Thickness In Patients
On Rimonabant) trial
- STRADIVARIUS : Strategy to Reduce
Atherosclerosis Development Involving Administration of Rimonabant-The
Intravascular Ultrasound Study trial
-
VICTORIA
:Visceral Fat Reduction
Assessed by CT-Scan on Rimonabant trial
- ADAGIO-Lipids : An International Study
of Rimonabant in dyslipidemia with AtheroGenic Risk in Abdominally
Obese Patients trial
Phase IIIb Trials
involving Type 2 Diabetes:
- SERENADE: Study Evaluating
Rimonabant Efficacy in Drug Naive Diabetic Patients
- ARPEGGIO: A Multicenter,
Randomized, Placebo-controlled, Double-Blind, Parallel-Group,
Fixed-Dose Study Evaluating the Effect of One Dose of rimonabant 20
mg/day on Glycemic Control in Type 2 Diabetic Patients Inadequately
Controlled With Insulin trial
- RAPSODI: Rimonabant in
Pre-Diabetic Subjects to Delay Onset of Type 2 Diabetes
|
RIMONABANT
CLINICAL TRIALS
|
- Rimonabant In Obesity
(RIO) trials
- RIO-Europe study
- RIO-Lipids study
- RIO-North America (NA)
study
- RIO-Diabetes study
|
- Studies with Rimonabant
and Tobacco Use (STRATUS)
- STRATUS-United States
study
- STRATUS-Europe study
- STRATUS-Worldwide study
|
PHASE
IIIB CLINICAL TRIALS TO ASSESS THE POTENTIAL ROLE OF THE RIMONABANT IN RISK
REDUCTION
|
Eight Studies to assess the potential role of the rimonabant in reducing
the risk of heart attacks or strokes in patients with an abdominal obesity
and other risk factors, and to explore use of rimonabant in preventing and
treating Type 2 diabetes |
Phase IIIb Trials
involving Cardiovascular Disease:
- CRESCENDO : Comprehensive Rimonabant
Evaluation Study of Cardiovascular END points and Outcomes trial
- AUDITOR : Atherosclerosis
Underlying Development Assessed By Intima-Media Thickness In Patients
On Rimonabant) trial
- STRADIVARIUS : Strategy to Reduce
Atherosclerosis Development Involving Administration of Rimonabant-The
Intravascular Ultrasound Study trial
-
VICTORIA
:Visceral Fat Reduction
Assessed by CT-Scan on Rimonabant trial
- ADAGIO-Lipids : An International Study
of Rimonabant in dyslipidemia with AtheroGenic Risk in Abdominally
Obese Patients trial
Phase IIIb Trials
involving Type 2 Diabetes:
- SERENADE: Study Evaluating
Rimonabant Efficacy in Drug Naive Diabetic Patients
- ARPEGGIO: A Multicenter,
Randomized, Placebo-controlled, Double-Blind, Parallel-Group,
Fixed-Dose Study Evaluating the Effect of One Dose of rimonabant 20
mg/day on Glycemic Control in Type 2 Diabetic Patients Inadequately
Controlled With Insulin trial
- RAPSODI: Rimonabant in
Pre-Diabetic Subjects to Delay Onset of Type 2 Diabetes
|
|
|
|
|
